Mergen Kılıç S.
AAN Annual Meeting, Washington, United States Of America, 2 - 07 April 2022, vol.98, no.13010, pp.2627, (Summary Text)
-
Publication Type:
Conference Paper / Summary Text
-
Volume:
98
-
Doi Number:
10.1212/wnl.98.18_supplement.2627
-
City:
Washington
-
Country:
United States Of America
-
Page Numbers:
pp.2627
-
Istanbul University Affiliated:
Yes
Abstract
Abstract
Objective:
To analyze the effect of intrathecal nusinersen in spinal muscular atrophy type 2 and type 3.
Background:
Spinal muscular atrophy (SMA) is an autosomal recessive, neurodegenerative disease caused by the mutations in the survival motor neuron 1 (SMN1) gene. Nusinersen is the first approved disease-modifying therapy in spinal muscular atrophy (SMA).
Design/Methods:
Herein, we evaluate the clinical features and treatment responses of 35 patients out of 52, treated with nusinersen with SMA type 2 or type 3 who completed the first four loading doses. Patients were treated with intrathecal administration at day 1 (baseline), day 29, day 85, and day 274, depending on a scheme defined by Turkey Pharmaceuticals and Medical Devices Agency. The remaining 17 patients are still on the first three loading doses.
Results:
The mean age of onset was 5.30 ± 4.47 (between 10 months and 16 years), and 18 patients were female. Thirty-one patients were type 3, and four patients were type 2. The mean age at the initial nusinersen dose was 26.32 ± 9.38 (between 13 and 47 years). Eighteen patients were ambulatory. Lumbar puncture was performed with X-Ray guidance in 5 patients due to severe scoliosis. The mean HMFSE score in the baseline visit was 31.28 ± 20.64 (between 0 and 60). In a mean duration of 573.22 ± 120.44 (between 299 and 770) days, HMFSE score was increased by 4.42 ± 3.32 (between 0 and 9) points. Increase in the HMFSE score was higher in type 3 patients compared to type 2 (2.25 vs. 4.70, p=0.04).
Conclusions: